Waltham, MA (PRWEB) April 19, 2017
ThermaGenix, the PCR Improvement Company, announces the completion of a $1.5M Series A-1 financing round. This event adds to several other early achievements at ThermaGenix, including the business formation and licensing agreements, and the establishment of its’ Executive and Scientific Teams.
ThermaGenix will use proceeds from the Series A-1 round to:
- Support commercial activities with its’ lead products- ThermaStopTM, ThermaStop-RT and ThermaGoTM –PCR additives that improve Polymerase fidelity and PCR product purity
- Broaden the range of assay utility with the LATE-PCR and Lights-On/Lights-Off application suite.
The Scientific Team at ThermaGenix have spent over 20 years investigating and improving virtually every aspect of PCR, RT-PCR and Multi-Plex PCR amplification of DNA and RNA. The ThermaStop and ThermaGo PCR additive reagents eliminate all forms of mis-priming before-during-and after PCR and RT-PCR amplification and thereby increase assay quality, quantitative accuracy, sensitivity, and multiplexing. Prof. Wangh’s team have generated more than 50 peer-reviewed publications and 10 Patents in the field of PCR and PCR Assays.
ThermaGenix (http://www.thermagenix.com) is a leading innovator and provider of PCR reagents and PCR Assays for use in the most widely adopted research processes involving DNA amplification strategies. ThermaGenix has a veteran team of Scientists with over 20 years experience working with PCR and DNA amplification strategies. In addition to the PCR reagents Therma-StopTM and Therma-GoTM, ThermaGenix has licensed non-symmetric LATE-PCR amplification of single-stranded DNA and Lights-On/Lights-Off probes and low-temperature probes for highly informative assays in a broad array of fields, including Species ID and Liquid Biopsy.